ELIEM THERAPEUTICS, INC.

Analyst Reco. Eliem Therapeutics, Inc.

Equities

ELYM

US28658R1068

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
7.71 ^USD	+0.65%		+4.05%	+185.56%

May. 15	Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Eliem Therapeutics to Neutral From Buy	23-02-10	MT
HC Wainwright Starts Eliem Therapeutics at Buy With $6 Price Target	22-10-28	MT
SVB Securities Adjusts Eliem Therapeutics' Price Target to $4 From $9, Keeps Outperform Rating	22-08-16	MT
SVB Securities Adjusts Eliem Therapeutics' Price Target to $9 from $13, Keeps Outperform Rating	22-07-11	MT
Guggenheim Downgrades Eliem Therapeutics to Neutral from Buy	22-04-26	MT
SVB Leerink Lowers Price Target for Eliem Therapeutics to $13 From $33, Maintains Outperform Rating	22-04-25	MT
ELIEM THERAPEUTICS : Evercore ISI Initiates Coverage on Eliem Therapeutics With Outperform Rating	21-09-08	MT
ELIEM THERAPEUTICS : Stifel Starts Eliem Therapeutics at Buy with $35 Price Target	21-09-07	MT
ELIEM THERAPEUTICS : SVB Leerink Starts Eliem Therapeutics at Outperform with $33 Price Target	21-09-07	MT
ELIEM THERAPEUTICS : Guggenheim Starts Eliem Therapeutics at Buy with $32 Price Target	21-09-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer